ACH — Accendra Health, Inc.

Summary of Accendra Health's Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: For Q4 2025, revenue was nearly $2.8 billion, reflecting a year-over-year growth of over 3%.
• Adjusted EBITDA: Q4 adjusted EBITDA was $90 million, down from $102.5 million in Q4 2024. Full-year adjusted EBITDA was $375 million, a slight increase from 2024.
• Cash Flow: Operating cash flow for Q4 was $68 million, with continuing operations generating $135 million. Full-year cash flow from continuing operations was $154 million.
• Debt Reduction: Net debt decreased to $1.8 billion, down $315 million from Q3 2025.
• Free Cash Flow: Q4 free cash flow was $18 million, with a full-year total of $98 million.

2. Strategic Updates and Business Highlights

• Market Position: Accendra Health serves approximately 300 million Americans, focusing on chronic conditions, particularly in home-based care.
• Technology Investments: The company is enhancing customer experience and operational efficiency through technology, including the upcoming launch of the MyApria app.
• Sleep Journey Initiative: Sales in sleep supplies grew by 8-9% in Q4, attributed to improved patient engagement and reordering processes.
• Divestiture Completion: The sale of the former Products & Healthcare Services business was completed, allowing Accendra to focus on core home-based care operations.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected annual revenue between $2.55 billion and $2.65 billion, with a significant impact from the loss of a large commercial payer contract.
• Adjusted EBITDA Guidance: Projected to be between $335 million and $355 million for 2026.
• Free Cash Flow Expectations: At least $100 million in free cash flow anticipated for 2026, with a focus on debt reduction and capital structure optimization.

4. Bad News, Challenges, or Points of Concern

• Contract Loss Impact: The loss of a large commercial payer is expected to reduce revenue by approximately $300 million in 2026, significantly affecting growth.
• Inflationary Pressures: Increased costs from suppliers and inflation are impacting margins, with collection rates also being a concern due to technology implementation challenges.
• Stranded Costs: Continued impact from stranded costs related to the pre-divestiture business, although these will be integrated into operating expenses moving forward.

5. Notable Q&A Insights

• Investment Strategy: Management emphasized a focus on technology investments to enhance customer experience while prioritizing debt reduction.
• Revenue Recovery: The company is exploring new agreements, such as with Optum, to help recover lost revenue, although full recovery is not expected.
• CapEx Guidance: Patient CapEx was $45 million in Q4, with expectations for it to represent about 95% of total CapEx in 2026.
• Market Dynamics: Management acknowledged that cost increases are not uniformly affecting all categories and are seen as opportunities for negotiation with manufacturers.

Overall, Accendra Health is navigating a transformative period post-divestiture, focusing on strengthening its core business while addressing challenges related to revenue loss and cost pressures.